



In association with




European Association  
for the Study of Diabetes

# CLEVELAND CLINIC ADVANCED CERTIFICATE COURSE IN DIABETES 2020

&

## EASD DIABETES SYMPOSIUM

29-30 AUGUST 2020



# ADVISORS



Dr. Banshi Saboo



Dr. Rajeev Chawla



Dr. Sanjay Agarwal



Dr. SR Aravind

**ORGANISING CHAIR/  
COURSE DIRECTOR-  
CLEVELAND CLINIC**



Dr. Adi E Mehta

**ORGANISING SECRETARY/  
COURSE DIRECTOR-  
INDIA**



Dr. B.M. Makkar

# ORGANISING COMMITTEE



Dr. J.K. Sharma



Dr. Purvi Chawla



Dr. Shalini Jaggi



Dr. Vipul Gupta



Dr. Amit Gupta



Dr. Girish Khurana



Dr. Dheeraj Kapoor



# CLEVELAND CLINIC FACULTY



Dr. Melissa Li-Ng



Dr. Adi E Mehta



Dr. Mario Skugor



Dr. Robert S. Zimmerman

# EASD FACULTY



Dr. Pratik Choudhary  
UK



Dr. Leszek Czupryniak  
Poland



Dr. Didac Mauricio  
Spain



Dr. Chantal Mathieu  
Belgium

# INDIAN FACULTY



Dr. V Mohan



Dr. AK Das



Dr. Shashank R Joshi



Dr. Anil Bhansali



Dr. Amit Gupta



Dr. Anuj Maheshwari




Dr. Arvind Gupta



Dr. Balbir Singh



Dr. Banshi Saboo



# INDIAN FACULTY



Dr. B.M. Makkar



Dr. Dheeraj Kapoor



Dr. Girish Khurana



Dr. Hemant Thacker



Dr. J.K. Sharma



Dr. Jothydev



Dr. Manoj Chawla



Dr. Neeta Deshpande




Dr. Rajeev Chawla



Dr. Rajiv Kovil



Dr. Sanjay Agarwal



Dr. SR Aravind



Dr. Sunil Gupta



Dr. Vijay Panikar




Dr. Vipul Gupta

# SCIENTIFIC PROGRAM



29 AUGUST 2020 Time zone (GMT+5.30)		CCACCD DAY 1	SPEAKER	MODERATOR
CLEVELAND TIME	INDIA TIME			
<b>SESSION 1</b> <b>4.30-7.15AM</b>	<b>SESSION 1</b> <b>2.00-4.45PM</b>	<b>Opening Remarks And Introduction-15 Minutes</b>	<b>BM Makkar</b>	
4.45-5.15AM	2.15-2.45pm	Nutritional Management in Diabetes	Shashank Joshi	
5.15-5.45AM	2.45-3.15pm	Diabetes Paradoxes	Anil Bhansali	Bansi Saboo Rajiv Kovil Neeta Deshpande
5.45-6.15AM	3.15-3.45pm	Metabolic Flexibility	BM Makkar	
6.15-6.45AM	3.45-4.15pm	Diabetes And COVID	Shashank Joshi	
6.45-7.15AM	4.15-4.45pm	DISCUSSION		
<b>7.15-7.30AM</b>	<b>4.45-5.00PM</b>	<b>Opening Remarks And Introduction</b>	<b>Cleveland Faculty</b>	
<b>PLENARY SESSION 1</b> <b>7.30-8.00AM</b>	<b>PLENARY SESSION 1</b> <b>5.00-5.30PM</b>	<b>Hypertriglyceridemia And CV Risk – Back In Action</b>	<b>Adi Mehta</b>	Sanjay Agarwal Manoj Chawla
<b>DEBATE 1</b> <b>8.00-8.30AM</b>	<b>DEBATE 1</b> <b>5.30-6.00PM</b>	<b>WHAT IS PRIMARY IN DIABETES MANAGEMENT</b> <b>ASCVD Risk Reduction Is Primary - Hyperglycemia Management Is Primary –</b>	<b>R Chawla</b> <b>BM Makkar</b>	Adi Mehta Robert Zimmerman
<b>ESC LIVE SESSION</b> <b>8.30-9.15AM</b>	<b>ESC LIVE SESSION</b> <b>6.00-6.45PM</b>	<b>EMPEROR-Reduced: Empagliflozin in Heart Failure With a Reduced Ejection Fraction, With and Without Diabetes</b>	<b>Live Webcast from ESC</b>	Balbir Singh SR Aravind
	<b>DISCUSSION</b>	<b>CLEVELAND CLINIC FACULTY+</b>		

# SCIENTIFIC PROGRAM



<b>PLENARY SESSION 2</b>	<b>PLENARY SESSION 2</b>	Type 2 Diabetes Is Not One Disease: New Evidence From Clustering Of Diabetes In India	V Mohan	Adi Mehta Mario Skugor
<b>SESSION 2</b> <b>9.45-11.15AM</b>	<b>SESSION 2</b> <b>7.15-8.30PM</b>	<b>ONGOING LEARNINGS FROM LANDMARK TRIALS</b>		AK Das Vijay Panikar Purvi Chawla
9.45-10.00AM	7.15-7.30PM	DCCT/EDIC	Robert Zimmerman	AK Das Vijay Panikar Purvi Chawla
10.00-10.15AM	7.30-7.45PM	UKPDS	Mario Skugor	
10.15-10.30AM	7.45-8.00PM	Legacy Effect – What Have We Learnt?	Adi Mehta	
10.30-10.45AM	8.00-8.15PM	TEDDY & T1GER	Robert Zimmerman	
10.45-11.00AM	8.15-8.30PM	VERIFY	Melissa Li-Ng	
11.00-11.15AM	8.30-8.45PM	DISCUSSION		
<b>SESSION 3</b> <b>11.15AM-12.30PM</b>	<b>SESSION 3</b> <b>8.45-10.00PM</b>	<b>PAST, PRESENT, FUTURE</b>		JK Sharma Dheeraj Kapoor
11.15-11.35AM	8.45-9.05PM	Sulfonylureas	Melissa Li Ng	JK Sharma Dheeraj Kapoor
11.35-11.55AM	9.05-9.25PM	Pioglitazone	Adi Mehta	
11.55AM-12.15PM	9.25-9.45PM	DPP4 Inhibitors	Mario Skugor	
12.15-12.30PM	9.45-10.00PM	DISCUSSION		

30 AUGUST 2020 TIME ZONE (GMT+5.30)	CCACCD DAY 2	SPEAKER	MODERATOR
<b>WORKSHOPS</b>			
<b>CLEVELAND TIME</b>	<b>INDIA TIME</b>		
3.30-4.30AM	11.00AM-12.00PM	Point of Care Testing	Rajeev Chawla
4.30-5.30AM	12.00-1.00PM	Glucose Monitoring Technologies – What Works for India?	Jothydev Kesavdev
5.30-6.30AM	1.00-2.00PM	WORKSHOP OF TIR/GLYCEMIC VARIABILITY – NOVO NORDISK	Jothydev Kesavdev Manoj Chawla

# SCIENTIFIC PROGRAM



UK TIME 9.30AM-12.15PM	INDIA TIME 2.00-4.45PM	EASD DIABETES SYMPOSIUM		
9.30-10.00AM	2.00-2.30PM	SGLT2 Inhibitors – Are They All Same?	Leszek Czupryniak	
10.00-10.30AM	2.30-3.00PM	Real World Data From 2nd Generation Basal Insulins - Are They Worth It	Didac Mauricio	Banshi Saboo Neeta Deshpande
10.30-11.00AM	3.00-3.30PM	Update On Closed Loop Systems For Type 1 Diabetes	Pratik Choudhary	
11.00-11.30AM	3.30-4.00PM	Prevention of Type 1 Diabetes	Chantal Mathieu	
11.30-11.45AM	4.00-4.15PM	DISCUSSION		
11.45AM-12.15PM	4.15-4.45.00PM	PANEL DISCUSSION – Barriers To Adoption Of Technologies For Diabetes Management In India	EASD Faculty	Banshi Saboo, Neeta Deshpande, Jothydev, Manoj Chawla, Rajeev Kovil
<b>5.00PM-10.00PM (GMT+5.30)</b>		<b>CCACCD DAY2</b>		
CLEVELAND TIME	INDIA TIME			
7.15AM-7.30AM	4.45-5.00PM	RECAP OF DAY 1		BM Makkar
<b>SESSION 4</b>	<b>SESSION 4</b>			Sanjay Agarwal
7.30AM-8.45AM	5.00-6.15PM	<b>SGLT2 Inhibitors Update</b>		Shalini Jaggi
7.30-7.45AM	5.00-5.15PM	CREDENCE – Changing Diabetes Management Perspective	Melissa Li Ng	
7.45-8.00AM	5.15-5.30PM	DECLARE to DAPA HF – Dapagliflozin Hence Forth	Adi Mehta	Sanjay Agarwal Shalini Jaggi
8.00-8.15AM	5.30-5.45PM	EMPA-REG and Onwards	Mario Skugor	
8.15-8.30AM	5.45-6.00PM	Gliflozins – What's New?	Robert Zimmerman	
8.30-8.45AM	6.00-6.15PM	DISCUSSION		
<b>PLENARY SESSION 3</b>	<b>PLENARY SESSION 3</b>			Sunil Gupta
8.45AM-9.15AM	6.15-6.45PM	Future Of Insulin Therapy	Robert Zimmerman	Girish Khurana

# SCIENTIFIC PROGRAM



SESSION 5 9.15AM-10.30AM	SESSION 5 6.45-8.00PM			
9.15-9.35AM	6.45-7.05PM	Basal Insulin Analogues – Have They Revolutionized Insulin Therapy?	Adi Mehta	Arvind Gupta Amit Gupta
9.35-9.55AM	7.05-7.25PM	Weight Centric Management Of Diabetes	Mario Skugor	
9.55-10.15AM	7.25-7.45PM	Determining CV risk in Clinical Practice	Melissa Li Ng	
10.15-10.30AM	7.45-8.00PM	DISCUSSION		
DEBATE 10.30AM-11.15AM	DEBATE 8.00-8.45PM	Metformin Should Be Considered First Line Therapy For Diabetes Patients With ASCVD/At High Risk Of ASCVD.	No – Adi Mehta Yes – BM Makkar	SR Aravind Hemant Thacker
SESSION 6 11.15AM-12.30PM	SESSION 6 8.45-10.00PM			
11.15-11.35AM	8.45-9.05PM	Cardio-Renal Risk Reduction In Diabetes – Changing Paradigm	Melissa Li Ng	Anuj Maheshwari Vipul Gupta
11.35-11.55AM	9.05-9.25PM	New GLP1 RAs – Are They Different	Mario Skugor	
11.55AM-12.15PM	9.25-9.45PM	Newer Glucose Sensing Technologies	Robert Zimmerman	
12.15-12.30PM	9.45-10.00PM	DISCUSSION		
12.30PM-12.45PM	10.00-10.15PM	CLOSING REMARKS		Cleveland Faculty

## CONFERENCE SECRETARIAT



**Dr. B. M. Makkar**  
Organising Secretary & Course Director,  
India Diabetes and Obesity Centre  
A - 5B/122, Paschim Vihar, New Delhi - 110 063  
Tel: +91 11 2526 7671 / 2528 0150  
Mob: +91 9811 077419  
Email: drbmmakk@gmail.com  
drbmmakk@yahoo.com  
ccaccd@itindustries.com

## VIRTUAL EVENT HELPDESK



ITIndustries.com  
Tel: +91 124 4079071  
Mob: +91 9810232774  
Email: info@itindustries.com

## REGISTER ON

<https://ccaccd.com/2020/Registration.html>